|
rs121913514
|
|
|
0.030 |
GeneticVariation |
BEFREE |
N822K- or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells.
|
31484543 |
2019 |
|
rs121913521
|
|
|
0.020 |
GeneticVariation |
BEFREE |
N822K- or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells.
|
31484543 |
2019 |
|
rs10740055
|
|
|
0.010 |
GeneticVariation |
BEFREE |
It was found that the variants rs10740055 of ARID5B and rs6964823 of IKZF1 act individually and additively as risk factors in the development of leukemia in the populations of Jammu and Kashmir in Northern India.
|
30810385 |
2019 |
|
rs138817062
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Although HIPK2 mutations (R861W and N951I) were found in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients, little is known about the underlying mechanisms by which HIPK2 mutations are associated with the pathogenesis of leukemia.
|
30755814 |
2019 |
|
rs2853677
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The results of this study suggested that rs2853677 of TERT signifies association in multiple cancers and suggests that it can become potential marker for diagnosis of non-small cell lung cancer and leukemia.
|
31126249 |
2019 |
|
rs3116496
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CONCLUSIONS Our meta-analysis confirmed that rs3116496 was significantly related to cancer risk, especially in an Asian population, and was strongly correlated with the increased risk of breast cancer, leukemia and colorectal cancer.
|
30867406 |
2019 |
|
rs6964823
|
|
|
0.010 |
GeneticVariation |
BEFREE |
It was found that the variants rs10740055 of ARID5B and rs6964823 of IKZF1 act individually and additively as risk factors in the development of leukemia in the populations of Jammu and Kashmir in Northern India.
|
30810385 |
2019 |
|
rs7090445
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Genetic analyses revealed a novel heterozygous mutation in the ETS domain of <i>ETV6</i> (c.1136T>C, p.Leu379Pro) along with absence of heterozygosity of chromosome (10)(q21.2q21.3), yielding a biallelic leukaemia risk allele in <i>ARID5B</i> (rs7090445-C).
|
31704777 |
2019 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Collectively, the present results suggest that in the treatment of leukemia, taxodione has potential as a compound with high efficacy to overcome BCR-ABL T315I mutation-mediated resistance in leukemia cells.
|
29859988 |
2018 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system.
|
29967475 |
2018 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Antitumor Effects of Blocking Protein Neddylation in T315I-BCR-ABL Leukemia Cells and Leukemia Stem Cells.
|
29321163 |
2018 |
|
rs113488022
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Our results confirm that BRAF V600E-positive HCL is a relatively rare disorder in the Japanese leukemia patient population.
|
30043333 |
2018 |
|
rs121913377
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Our results confirm that BRAF V600E-positive HCL is a relatively rare disorder in the Japanese leukemia patient population.
|
30043333 |
2018 |
|
rs121913507
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Dasatinib overrides the differentiation blockage in a patient with mutant-<i>KIT</i> D816V positive CBFβ-MYH11 leukemia.
|
29545943 |
2018 |
|
rs121913682
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Dasatinib overrides the differentiation blockage in a patient with mutant-<i>KIT</i> D816V positive CBFβ-MYH11 leukemia.
|
29545943 |
2018 |
|
rs1360131632
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Collectively, the present results suggest that in the treatment of leukemia, taxodione has potential as a compound with high efficacy to overcome BCR-ABL T315I mutation-mediated resistance in leukemia cells.
|
29859988 |
2018 |
|
rs1799782
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Progression to secondary myelofibrosis/leukemia is influenced by exposure to cytoreductive agents, and caspase and BER polymorphisms {globally, CASP8 3'untranslated region [odds ratio (OR)=0.24; 95% confidence interval (CI), 0.08‑0.69], XRCC1 Arg194Trp [OR=3.58; 95% CI, 0.98‑13.01]; for essential thrombocythemia patients CASP9 Arg173His [OR=11.27; 95% CI, 1.13‑112.28], APEX1 Asp148Glu [OR=0.28; 95% CI, 0.74‑1.03], and XRCC1 Arg194Trp [OR=6.60; 95% CI, 1.60‑27.06]}.
|
30320340 |
2018 |
|
rs1057519866
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Here we use a conditional-and-inducible leukaemia model to demonstrate that expression of NT5C2(R367Q), a highly prevalent relapsed-ALL NT5C2 mutation, induces resistance to chemotherapy with 6-mercaptopurine at the cost of impaired leukaemia cell growth and leukaemia-initiating cell activity.
|
29342136 |
2018 |
|
rs1130409
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Progression to secondary myelofibrosis/leukemia is influenced by exposure to cytoreductive agents, and caspase and BER polymorphisms {globally, CASP8 3'untranslated region [odds ratio (OR)=0.24; 95% confidence interval (CI), 0.08‑0.69], XRCC1 Arg194Trp [OR=3.58; 95% CI, 0.98‑13.01]; for essential thrombocythemia patients CASP9 Arg173His [OR=11.27; 95% CI, 1.13‑112.28], APEX1 Asp148Glu [OR=0.28; 95% CI, 0.74‑1.03], and XRCC1 Arg194Trp [OR=6.60; 95% CI, 1.60‑27.06]}.
|
30320340 |
2018 |
|
rs139834892
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Progression to secondary myelofibrosis/leukemia is influenced by exposure to cytoreductive agents, and caspase and BER polymorphisms {globally, CASP8 3'untranslated region [odds ratio (OR)=0.24; 95% confidence interval (CI), 0.08‑0.69], XRCC1 Arg194Trp [OR=3.58; 95% CI, 0.98‑13.01]; for essential thrombocythemia patients CASP9 Arg173His [OR=11.27; 95% CI, 1.13‑112.28], APEX1 Asp148Glu [OR=0.28; 95% CI, 0.74‑1.03], and XRCC1 Arg194Trp [OR=6.60; 95% CI, 1.60‑27.06]}.
|
30320340 |
2018 |
|
rs2308950
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Progression to secondary myelofibrosis/leukemia is influenced by exposure to cytoreductive agents, and caspase and BER polymorphisms {globally, CASP8 3'untranslated region [odds ratio (OR)=0.24; 95% confidence interval (CI), 0.08‑0.69], XRCC1 Arg194Trp [OR=3.58; 95% CI, 0.98‑13.01]; for essential thrombocythemia patients CASP9 Arg173His [OR=11.27; 95% CI, 1.13‑112.28], APEX1 Asp148Glu [OR=0.28; 95% CI, 0.74‑1.03], and XRCC1 Arg194Trp [OR=6.60; 95% CI, 1.60‑27.06]}.
|
30320340 |
2018 |
|
rs371769427
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Sequencing DNA from the three AMLs revealed somatic mutations homologous to those considered to be drivers of human AML, including predicted loss- or gain-of-function mutations in <i>Tet2</i>, <i>Gata2</i>, <i>Idh1</i>, and <i>Ikzf1</i> However, the engineered <i>U2af1</i>(S34F) missense mutation reverted to WT in two of the three AML cases, implying that <i>U2af1</i>(S34F) is dispensable, or even selected against, once leukemia is established.
|
30322915 |
2018 |
|
rs4938723
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The main results were observed in the stratified analysis subgroups in cancer type subgroup: rs4938723 polymorphism may be a protective factor in leukemia, colorectal cancer, and esophageal cancer; however, C-allele was a risk factor in carriers for hepatocellular carcinoma.
|
30286050 |
2018 |
|
rs754944509
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Thus, the aim of this study was to investigate the effects of Shb knockout on the development of leukemia in three additional models, that is, colony stimulating factor 3 receptor-T618I-induced neutrophilic leukemia, p190 Breakpoint cluster region-cAbl oncogene 1 tyrosine kinase-induced B-cell leukemia, and G12D-Kras-induced T-cell leukemia/thymic lymphoma.
|
29792386 |
2018 |
|
rs766274360
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Progression to secondary myelofibrosis/leukemia is influenced by exposure to cytoreductive agents, and caspase and BER polymorphisms {globally, CASP8 3'untranslated region [odds ratio (OR)=0.24; 95% confidence interval (CI), 0.08‑0.69], XRCC1 Arg194Trp [OR=3.58; 95% CI, 0.98‑13.01]; for essential thrombocythemia patients CASP9 Arg173His [OR=11.27; 95% CI, 1.13‑112.28], APEX1 Asp148Glu [OR=0.28; 95% CI, 0.74‑1.03], and XRCC1 Arg194Trp [OR=6.60; 95% CI, 1.60‑27.06]}.
|
30320340 |
2018 |